Suchergebnisse

Rollins, Inc. ROL is set to report its first-quarter 2026 results on April 22, after the closing bell.

The company’s earnings surprise history has been impressive. It surpassed the Zacks Consensus

Novo Nordisk NVO announced meeting both co-primary endpoints in a late-stage study of its investigational candidate, etavopivat, for adults and adolescents with sickle cell disease (SCD). The data

AI memory giant Sandisk first came on our radar last year following its separation from Western Digital. The company was formerly Western Digital’s flash memory business that was spun off and

Microsoft MSFT and Alibaba BABA lead Western and Chinese cloud-AI markets, respectively, both pouring capital into generative models, agentic platforms and custom silicon. With upcoming quarterly

AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated its blockbuster rare disease drug Ultomiris (ravulizumab) for IgA

Nokia Corporation NOK is set to report first-quarter 2026 results on April 23, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 23.53%. It pulled

Hospital operator Universal Health Services, Inc. UHS is set to report first-quarter 2026 results on April 27, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported

Comcast CMCSA is scheduled to report its first-quarter 2026 results on April 23.The Zacks Consensus Estimate for first-quarter earnings is pegged at 73 cents per share, down 18.18% over the past 30

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval for both intravenous (“IV”) and subcutaneous (under the skin or SC)